PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
213 hedge funds and large institutions have $1.18B invested in PDL BioPharma, Inc. in 2015 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 73 increasing their positions, 69 reducing their positions, and 25 closing their positions.
118% more call options, than puts
Call options by funds: $3.29M | Put options by funds: $1.51M
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
25% more capital invested
Capital invested by funds: $946M → $1.18B (+$234M)
4% more funds holding
Funds holding: 204 → 213 (+9)
6% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$22.2M |
| 2 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$6.21M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$5.16M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$2.98M |
| 5 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
+$2.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$16.2M |
| 2 |
Renaissance Technologies
New York
|
-$14.5M |
| 3 |
GAM
Gotham Asset Management
New York
|
-$12.5M |
| 4 |
LCP
Lombardia Capital Partners
Pasadena,
California
|
-$10.5M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.47M |
PDLI Hedge Fund Activity: Q3 2015 in Review
213 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2015, worth a combined $1.18B — up 25% from $946M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PDLI positions and 25 closed out — a net gain of 9 holders — while 73 added to existing stakes and 69 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $22.2M. The largest seller was Bank of Montreal, cutting an estimated $16.2M.
- 213 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2015, up from 204 in Q2 2015.
- Funds reported $1.18B of PDL BioPharma, Inc. stock for Q3 2015, up 25% quarter-over-quarter.
- 34 funds opened new PDL BioPharma, Inc. positions in Q3 2015 and 25 closed out, a net change of +9 holders.
- The largest PDL BioPharma, Inc. buyer in Q3 2015 was First Trust Advisors, an estimated $22.2M added.
- The largest PDL BioPharma, Inc. seller in Q3 2015 was Bank of Montreal, an estimated $16.2M sold.
Based on aggregated 13F filings for Q3 2015.